Glucotrack Inc. (NASDAQ: GCTK), a medical technology company based in Rutherford, New Jersey, is making significant strides in transforming the continuous glucose monitoring (CGM) market. The company’s innovative implantable Continuous Blood Glucose Monitor (CBGM) is designed to address several challenges posed by existing CGM devices, such as real-time accuracy, frequent sensor changes, and user comfort.
Unlike other devices that measure glucose in interstitial fluids, Glucotrack’s CBGM measures glucose directly in the blood, providing accurate, real-time readings. This technological advancement sets Glucotrack apart from its competitors, as it offers a device that can last up to three years, eliminating the need for frequent replacements and minimizing the discomfort associated with adhesive wearables.
Glucotrack has been actively promoting the potential of its CBGM, showcasing its developments at key industry events. In June, the company presented two posters at the American Diabetes Association (ADA) 84th Scientific Sessions, a premier diabetes conference. The presentations focused on preclinical animal studies and a sensor longevity simulation model for the CBGM.
Further exposure came in August when Glucotrack presented an emerging science industry poster at the Association of Diabetes Care and Education Specialists annual conference. The poster highlighted market research data indicating that over 50% of potential users with type 1 and type 2 diabetes showed a positive sentiment towards the CBGM concept, suggesting it could be a viable alternative to existing products.
Supporting its claims, Glucotrack recently completed a 90-day preclinical study that demonstrated the CBGM’s sustained accuracy. The study reported a Mean Absolute Relative Difference (MARD) of 4.7% at day 90, a metric considered highly accurate for glucose monitoring devices. This study, which included more animal subjects and a longer duration than an earlier 60-day study, further validates the CBGM’s performance.
Glucotrack's president and CEO, Paul Goode, PhD, expressed optimism about the results, stating, “Our CBGM’s ability to continuously measure blood glucose for 3 years with accuracy, minimal calibration, and without a wearable device represents a significant advancement in glucose monitoring. We believe this technology has the potential to greatly improve the quality of life for people with diabetes by providing a more convenient and discreet monitoring solution.”
The company’s progress has attracted investment, securing $4 million in funding from its leading shareholder in July. This funding will support the upcoming first-in-human clinical trial, marking a critical step towards bringing the technology to market.
Glucotrack’s leadership team brings a wealth of experience to the table, with key figures like Paul Goode and Mark Tapsak, PhD, having held significant roles in major medical technology companies such as DexCom Inc. (NASDAQ: DXCM). The company recently strengthened its board with the appointment of Andy Balo, a former DexCom executive, who brings decades of regulatory, clinical, and quality experience.
With the continuous glucose monitoring market projected to grow at a compound annual growth rate (CAGR) of 10.3% from 2024 to 2034, Glucotrack’s advancements position it well to play a significant role in expanding options for diabetes patients. As the company moves towards human trials, its commitment to revolutionizing glucose monitoring appears to be progressing steadily.
Featured photo by Mykenzie Johnson on Unsplash.
